RSS | Login | Register

VIRACEPT

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare VIRACEPT to:

Generic Name for VIRACEPT

Nelfinavir (as mesylate) 250mg, 625mg; tabs.

Legal Classification:

Pharmacological Class for VIRACEPT

HIV-1 protease inhibitor.

Manufacturer of VIRACEPT

Agouron Pharmaceuticals

Indications for VIRACEPT

HIV infection.

Adults and Children:

Take with food. May dissolve tab and mix in small amount of water; powder may be mixed with a small amount of non-acidic food or beverage. <2yrs: not recommended. 2–13yrs: 20–30mg/kg 3 times daily; max 750mg 3 times daily. >13yrs: 1.25g twice daily or 750mg 3 times daily. Reduce concomitant rifabutin dose by ½ and give nelfinavir 1.25g twice daily.

Also:

VIRACEPT ORAL POWDER

Contraindications for VIRACEPT

CYP3A substrates that may cause serious events if blood levels are elevated (eg, cisapride, pimozide, midazolam, triazolam, lovastatin, simvastatin, ergots, amiodarone, quinidine).

Precautions for VIRACEPT

Hepatic impairment. Diabetes. Monitor for hyperglycemia or fat redistribution, hemophiliacs for spontaneous bleeding. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions for VIRACEPT

See Contraindications. Rifampin, St. John's wort: not recommended. Potentiates CYP3A substrates (eg, dihydropyridine calcium channel blockers, cyclosporine, tacrolimus, sirolimus, rifabutin, atorvastatin), sildenafil (max 25mg in 48 hours), phenytoin (monitor). Nelfinavir levels decreased by CYP3A inducers (eg, phenytoin, rifampin, carbamazepine, phenobarbital) or CYP2C19 inducers. Nelfinavir levels increased by CYP3A or CYP2C19 inhibitors. Antagonizes methadone, oral contraceptives (use additional or alternative contraception). Indinavir, ritonavir, saquinavir increase nelfinavir levels. Concomitant azithromycin: monitor for azithromycin toxicity (eg, elevated liver enzymes). Others: see literature.

Adverse Reactions for VIRACEPT

Diarrhea, nausea, flatulence, abdominal pain, rash, redistribution of body fat, diabetes, hyperglycemia.

How is VIRACEPT supplied?

Tabs 250mg—270, 300
625mg—120
Oral Pwd—144g

Related Disease:

HIV~antivirals

FDA reviews cardiac risk of Invirase in combination with Norvir

February 23, 2010

The FDA has notified healthcare professionals and patients that it is reviewing clinical trial data about a potentially serious effect on the heart associated with the use of Invirase (saquinavir, from Roche) in combination with Norvir (ritonavir, from Abbott).

Heat-stable Norvir tablets approved

February 16, 2010

The FDA has approved a heat-stable formulation of Norvir tablets (ritonavir, from Abbott) that can be stored at room temperature.

Videx and Videx EC labeling revised to include risk of non-cirrhotic portal hypertension

January 29, 2010

The FDA has notified healthcare professionals and patients that the use of Videx or Videx EC (didanosine, from Bristol-Myers Squibb) may cause non-cirrhotic portal hypertension, a rare but serious complication.

Prezista labeling updated to include 96-week data

January 28, 2010

Tibotec Therapeutics announced that the FDA has approved an updated label for Prezista (darunavir tablets) which includes 96-week data from the ARTEMIS and TITAN studies.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).